Why Ingevity Might Be On Your Radar Now

Ingevity (NGVT) has drawn attention recently as investors reassess the business after a period in which the stock has moved differently over the past month and past three months compared with its longer-term record.

The current share price of $74.74 sits against a 1 month share price return of 5.91% and a year to date share price return of 24.38%. The 1 year total shareholder return of 126.28% contrasts with a 5 year total shareholder return decline of 12.07%, which indicates that momentum has been stronger in the recent period than over the longer term.

If this kind of sharp re rating catches your eye, it can be helpful to see where else price and fundamentals are starting to line up in the market, starting with solid balance sheet and fundamentals stocks screener (44 results)

With Ingevity trading at $74.74, a value score of 2, an estimated intrinsic discount of about 48% and only a small gap to the US$80.50 analyst target, is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 7.2% Undervalued

At $74.74, the most followed narrative sees fair value for Ingevity at $80.50, leaving a modest gap that hinges on how margins and earnings evolve.

Accelerated portfolio repositioning and the advanced-stage divestiture of non core, lower margin businesses (Industrial Specialties and CTO refinery) are expected to drive a step change in margin profile, enabling greater focus and capital allocation toward higher growth, value added specialty chemicals, supporting both revenue quality and sustained EBITDA margin improvement.

Curious what kind of revenue mix, margin profile and future earnings multiple are baked into that $80.50 fair value? The underlying assumptions sketch a very specific path for profit recovery, cash generation and how the market might value those earnings by the end of the decade.

Result: Fair Value of $80.50 (UNDERVALUED)

However, the story could change quickly if tariff pressures persist on Advanced Polymer Technologies or if further impairment charges follow the recent US$184m and US$109.3m hits.

Another Angle On Ingevity’s Valuation

The narrative and fair value of $80.50 lean on earnings forecasts, but the current price of $74.74 also embeds a P/S ratio of 2.3x. That is richer than the US Chemicals industry at 1.1x, peers at 1.2x, and a fair ratio estimate of 1.6x, which points to less obvious room for error.

For anyone comparing price-to-sales-based checks against future earnings-based stories, the tension is clear. Does the market lean toward the fair ratio over time, or continue to support the current premium multiple around 2.3x on sales, given the company’s risks and balance sheet?

Next Steps

If this mix of risks and rewards leaves you on the fence, it can help to test the numbers yourself and quickly stress test your own assumptions using our breakdown of 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If you stop at just one stock, you risk missing out on other opportunities that might fit your goals even better, so consider casting the net a bit wider.

• Spot potential value opportunities early by scanning screener containing 25 high quality undiscovered gems that pair strong fundamentals with limited market attention.
• Prioritise resilience by reviewing 72 resilient stocks with low risk scores that keep risk scores tight while still offering exposure to equity returns.
• Focus on quality at a sensible price by checking 53 high quality undervalued stocks that combine healthier cash flows with balance sheets that look more robust.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.